STAAR Surgical Adjourns Stockholders Meeting for Merger

Staar Surgical ( (STAA) ) just unveiled an update.

On October 23, 2025, STAAR Surgical announced the adjournment of its special stockholders meeting, originally scheduled for the same day, to November 6, 2025. This meeting is intended to vote on the merger agreement with Alcon, a global leader in eye care. The adjournment allows more time for stockholders to consider the merger proposal, which could significantly impact STAAR’s operations and market positioning.

The most recent analyst rating on (STAA) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.

Spark’s Take on STAA Stock

According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.

Staar Surgical’s overall stock score is primarily impacted by its financial performance and technical analysis. The company is facing significant financial headwinds, with declining revenues and negative profitability metrics. Technical indicators suggest bearish momentum, further weighing on the stock’s outlook. The negative P/E ratio and lack of dividend yield also contribute to a lower valuation score.

To see Spark’s full report on STAA stock, click here.

More about Staar Surgical

STAAR Surgical, headquartered in Lake Forest, California, is a global leader in implantable phakic intraocular lenses, which offer vision correction solutions that reduce or eliminate the need for glasses or contact lenses. The company has been dedicated to ophthalmic surgery since 1982 and specializes in designing, developing, manufacturing, and marketing advanced Implantable Collamer Lenses (ICLs). STAAR has sold over 3 million ICLs in more than 75 countries.

Average Trading Volume: 1,696,395

Technical Sentiment Signal: Sell

Current Market Cap: $1.32B

For detailed information about STAA stock, go to TipRanks’ Stock Analysis page.